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Abstract
Background: Wnt5a is a non-canonical secreted glycoprotein of the Wnt family that plays an important role in cancer
development and progression. Previous studies report that Wnt5a is upregulated in prostate cancer and suggested that
Wnt5a affects migration and invasion of prostate tumor cell. This study aimed to evaluate the prognostic value of Wnt5a
protein expression in prostate cancer tissue and its potential to predict outcome after radical prostatectomy in patients with
localized prostate cancer.
Methodology and Results: Immunohistochemical analysis of a tissue microarray containing prostate specimens of 503
patients with localized prostate cancer showed significantly higher Wnt5a protein expression in cancer compared to benign
cores from the same patients (p,0.0001). Patients with high expression of Wnt5a protein had significantly better outcome
in terms of time to biochemical recurrence compared to patients with low expression levels (p=0.001, 95%CI 1.361–3.570,
Hazard’s ratio 2.204). A combination of high Wnt5a expression with low levels of Ki-67 or androgen receptor expression had
even better outcome compared to all other groups. Furthermore, we found that Wnt5a expression significantly correlated
with VEGF and with Ki-67 and androgen receptor expression, although not highly significant. In vitro, we demonstrated that
recombinant Wnt5a decreased invasion of 22Rv1 and DU145 cells and that siRNA knockdown of endogenous Wnt5a protein
led to increased invasion of 22Rv1 and LNCaP cells.
Conclusion: We demonstrate that preserved overexpression of Wnt5a protein in patients with localized prostate cancer
predicts a favorable outcome after surgery. This finding together with our in vitro data demonstrating the ability of Wnt5a
to impair the invasive properties of prostate cancer cells, suggests a tumor suppressing effect of Wnt5a in localized prostate
cancer. These results indicate that Wnt5a can be used as a predictive marker and that it also is a plausible therapeutic target
for treatment of localized prostate cancer.
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Introduction
Prostate cancer (PCa) is the leading cancer affecting men of all
races and the second most leading cause of death in developed
countries [1]. Androgens and the androgen receptor (AR) play
critical roles not only in normal development, growth and function
of the prostate gland but also in carcinogenesis and progression of
PCa [2]. Initially, PCa cells are commonly AR dependent for their
growth and survival, and hence respond to androgen deprivation
therapy (ADT), but in later stages PCa cells become androgen-
insensitive, and fatal castration-resistant prostate cancer (CRPC)
develops [3]. The molecular mechanisms responsible for transition
into CRPC are poorly understood, however, the most consistent
change associated with castration-resistant growth in global gene
expression profiles of PCa xenografts was an increase in the AR
mRNA levels [4]. Increased expression of AR is considered to be a
key feature of CRPC and it has been demonstrated as a
consequence of either mutation or amplification of AR or by
increased expression caused by deregulated growth factors or
various co-regulators [5]. Although we have access to prognostic
factors in PCa, including Gleason grade, TNM stage, surgical
margin status and serum PSA levels, there is an urgent need to
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alone or in combination of other biomarkers, our ability to predict
outcome in PCa patients. Previous studies have suggested a
possible relationship between AR and Wnt-b-catenin signaling
pathways during the development and progression of PCa [6,7].
Recently, attention has been drawn to the role of Wnt proteins
and Wnt signaling in PCa. The name Wnt comes from ‘‘wingless-
related MMTV integration site’’ and was originally suggested by
Nusse and co-workers in 1991 [8]. Wnt proteins constitute a family
of nineteen secreted glycoproteins that play important roles during
development and in cell fate specification, cell migration and cell
polarity [9,10]. Wnt proteins can be classified into at least two
subfamilies; canonical Wnts that promote b-catenin-mediated
transcription and non-canonical Wnts. Wnt signaling occur in an
auto- or paracrine fashion through binding of secreted Wnt
molecules to seven transmembrane Frizzled receptor proteins (Fz)
in the absence or presence of co-receptors such as LRP 5/6 and
ROR [10]. Several Wnt signaling components have also been
implicated in genesis of human cancers; overexpression of Wnt-1
was observed in mammary epithelial adenocarcinoma [11] and in
several PCa cell lines and PCa tissues. Wnt-1 expression positively
correlated with Gleason score, b-catenin and with serum PSA
levels [12]. In addition, based on the determination of Wnt5a
mRNA levels in prostate tumors it has been suggested that
abnormal expression of the non-canonical Wnt5a is involved in
PCa [13].
Wnt5a, one of the most studied non-canonical Wnts, is an
essential Wnt protein in inducing and controlling the Wnt/planar
cell polarity (PCP) and the Wnt/Ca
2+ pathways [14,15]. In
addition, Wnt5a has not only been demonstrated to counteract the
Wnt/b-catenin pathway but also, in specific contexts, to activate
this pathway [16]. The possibility of Wnt5a to induce different
downstream signaling events can at least in part explain the
presence of reports suggesting an ambiguous nature of Wnt5a;
having either a tumor suppressor or tumor promoting function
depending on context and tumor type [16]. Previous studies have
shown that Wnt5a is downregulated in certain malignancies
including colorectal cancer (protein expression) [17], neuroblasto-
ma (mRNA levels) [18], invasive ductal breast carcinomas (protein
expression) [19,20] and leukemias (mRNA levels) [21], indicating
a tumor suppressing effect of Wnt5a. Interestingly, other reports
have instead suggested an oncogenic effect of Wnt5a primarily
based on an upregulation in breast cancer cells (mRNA levels)
[22], gastric cancer (protein expression) [23], melanoma (protein
expression) [24], lung cancer and prostate cancer (mRNA
expression) [13]. Aberrant gene and protein expression of Wnt5a
in PCa and possible underlying molecular mechanisms have been
described in previous reports [13,25,26,27]. In a recent study,
based on the Affymetrix studies of normal prostate epithelial and
cancer cell lines, Wang et al showed that increased transcription of
the Wnt5a gene in PCa was due to hypomethylation; suggesting
that epigenetic regulation of Wnt5a expression may be of
importance in PCa progression [28]. Any conclusion made from
data from an Affymetrix analysis without a simultaneous analysis
of Wnt5a protein expression is dangerous since the Wnt5a mRNA
has a long untranscribed 39-region open for translational
regulation. Data supporting such a translational regulation of
Wnt5a protein expression has previously been reported [19,29].
Recent studies have shown increased Wnt5a and protein levels
in PCa compared to benign tissue [25,26]. Yamamoto et al
demonstrated in vitro that knockdown of Wnt5a reduced the
invasive properties of DU145, and over-expression of Wnt5a
stimulated invasion of PC3 cells [25]. In contrast, Wang Q and co-
workers demonstrated that recombinant Wnt5a did not induce an
increased motility in the same PC3 cells [26]. In addition, it has
been shown by immunohistochemistry (IHC) that Wnt5a
expression correlated with Gleason score $8 in 24 patients from
a cohort of 98 PCa patients that had undergone radical
prostatectomy. This could indicate that Wnt5a promotes aggres-
siveness, since patients with low Wnt5a levels had a better relapse-
free survival compared to patients with high Wnt5a levels [25].
Conflicting reports on the role of Wnt5a in PCa progression and
sparse information about Wnt5a expression in relation to clinical
outcome, urged us to investigate protein expression of Wnt5a in a
large population-based cohort and its possible role to predict
outcome after surgery for localized and predominantly low-grade
(91%) PCa. This investigation was complemented with in vitro
experiments to explore possible reasons for the ability of Wnt5a to
act as a predictive biomarker in this patient category. In the
present study we confirmed that Wnt5a protein levels were
upregulated in PCa compared to benign tissue but we found that
increased Wnt5a protein expression had a positive effect on
outcome in PCa patients, as patients with high Wnt5a protein
levels had a better outcome compared to patients with low Wnt5a
levels after radical prostatectomy. In good agreement, we also
found that this ability of Wnt5a to positively affect outcome in PCa
patients might be due to its ability to inhibit invasion of PCa cells
without initially affecting their proliferation in vitro. Addition of
Foxy5 (a Wnt5a mimicking peptide) also decreased invasion but
not proliferation of these cells.
Results
Immunohistochemical evaluation of Wnt5a, AR, Ki-67 and
VEGF
A tissue microarray (TMA) construct with duplicate cores of
both benign and malignant tissues from 503 patients (patients’
characteristics in Table 1) that had undergone radical prostatec-
tomy, was immunostained for Wnt5a, AR, Ki-67 and VEGF
(Fig. 1A–F). Wnt5a protein expression was detected in the
cytoplasmic compartment of epithelial cells and occasionally in
stromal cells of both cancer and benign tissue specimens. Cancer
tissues from most patients (82%) showed a homogenous strong
Table 1. Summary of patient characteristics (n=503).
Characteristic Median (IQR) or Frequency (%)
Age at diagnosis (years) 63.13 (59.33, 66.18)
Preoperative PSA (ng/ml) 7.2 (5.03, 11.07)
Clinical Stage
T1 181
T2 233
T3 9
Pathological Gleason Score
#3+4 423 (84.1%)
$4+3 51 ((10.1%)
Extracapsular extension 250 (49.7%)
Seminal vesicle invasion 55 (10.9%)
Positive surgical margins 259 (51.5%)
Lymph node involvement (LNI)* 3 (2%)
Abbreviation: IQR, Interquartile range.
*Information about LNI was available only for 153 patients.
doi:10.1371/journal.pone.0026539.t001
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(65%) showed weak immunoreaction supporting that an up-
regulation of Wnt5a protein occurs in cancer tissue. Results from
manual scoring of cytoplasmic staining intensities in malignant
and benign epithelial cells are illustrated in Fig. 1G–I. The
difference between Wnt5a staining intensities in cancer and benign
samples was found to be significant (p,0.0001) when paired
Wilcoxon rank sum test was performed. In nearly 80% of the
patients we found strong Wnt5a staining intensity (arbitrary unit 2
or 3) in cancer cores, whereas only 35% patients displayed strong
staining in benign tissue samples. Further details on the scoring
data from Wnt5a, AR, Ki-67 and VEGF stained cores are given in
Table 2.
Androgen receptor staining was predominantly nuclear as
expected and in general more intense in cancer compared to
benign tissue specimens as detailed in Table 2. Seventy per cent
of tumor cores were intensely stained compared to 53% of benign
cores.
Nuclear Ki-67 expression was used as a proliferation marker
(Figure S1A,B,C,D). There were significant differences in Ki-67
staining between cancer and benign cores, as 14% of the benign
cores were negative for Ki-67, whereas only 5% of the cancers
cores were Ki-67 negative. Regarding positive Ki-67 nuclear
staining, nearly 9% of the cancer cores had a staining score more
than 2, whereas the corresponding number for the benign cores
was only 2.5% (Table 2).
VEGF expression, as a surrogate marker for angiogenesis, was
observed in the cytoplasm of both malignant and benign epithelial
cells, with cancer areas showing higher staining compared to
benign. More than 73% of the cancer cores showed strong VEGF
Figure 1. Immunohistochemical expression of Wnt5a, AR and VEGF in tissue microarray cores of primary tumors and benign
specimens obtained after radical prostatectomy. A & B) The panels show representative Wnt5a immunostainings in benign and cancer tissue
areas from the same patient C&D ) The panels show representative nuclear AR immunostainings in benign and cancer tissue areas E&F ) The panels
outline VEGF immunostaining in benign and cancer tissue areas from the same patient. All inserts in the panels depict magnification (406) images of
the area indicated by the arrow in the larger image seen at 156magnification. G, H & I) The panels outline graphical illustrations of Wnt5a, AR and
VEGF protein expressions in benign and cancer samples in PCa patients. The bar in each panel outlines 100 mm.
doi:10.1371/journal.pone.0026539.g001
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strong immunoreaction (Table 2).
The difference between AR, Ki-67 and VEGF staining
intensities in cancer versus benign cores was statistically significant
(p,0.0001) when Wilcoxon rank sum test was performed
(Table 2).
Correlation of Wnt5a tissue expression with AR, Ki-67 and
VEGF
In the present cohort Wnt5a expression showed a positive and
statistically significant correlation with VEGF expression (Spear-
man’s rho (r)=0.396, p,0.0001), weak but still statistically
significant correlations with AR expression (r=0.159, p=0.007)
and Ki-67 expression (r=0.233, p,0.0001) (Table 3). Most of
the patients (220/365, 60%) with strong Wnt5a immunostaining in
cancer tissues also exhibited intense AR staining (Table 4). A
similar trend was observed when Wnt5a and VEGF were
compared; 65% (219/339) of the cancer cores exhibited strong
staining for both Wnt5a and VEGF. We found no differences in
Wnt5a immunostaining intensity when we compared groups of
patients with different Gleason scores. Among patients with
pathological Gleason score up to 3+4 (‘‘low grade’’), 81% had
elevated Wnt5a protein expression compared to 86% of the
patients with higher Gleason score (data not shown). Similarly, no
correlation was observed between Wnt5a staining and patholog-
ical T stage, clinical T stage, surgical margin status or seminal
vesicle invasion (data not shown).
Wnt5a protein expression and prediction of clinical
outcome
Next, we evaluated if Wnt5a protein expression in cancer tissues
analyzed after radical prostatectomy for localized PCa could
predict clinical outcome as measured by time to biochemical
recurrence (BCR), using PSA .0.2 ng/mL in blood samples with
a confirmatory value as a surrogate marker. Wnt5a protein
expression as illustrated by IHC was significantly higher in cancer
areas compared to benign areas (Fig. 1, Table 2). Interestingly,
when Kaplan-Meier curve was plotted between Wnt5a protein
expression and BCR free time, a favourable outcome (p=0.001)
was evident for patients with a high Wnt5a protein expression
compared to patients with low Wnt5a protein expression (Fig. 2A).
As expected, low expression of AR (Figure S2C) and of Ki-67
(Figure S2B) was associated with favorable outcome whereas
VEFG expression was not significantly associated with BCR free
time (Figure S2D).
Further, we examined if Wnt5a protein expression also could
predict outcome when combined with any of the other tissue
biomarkers. The best prediction model was obtained when Wnt5a
protein expression was combined with either AR or Ki-67
expression (Fig. 2B, C), as patients with high Wnt5a and low
AR or low Ki-67 expression showed better relapse free survival
(p,0.0001), whereas patients with low Wnt5a expression and high
AR or high Ki-67 expression had the worst outcome after surgery.
Patients with high Wnt5a and low VEGF expression had better
outcome compared to other groups (p=0.003) or each marker
alone. However, the combination of high Wnt5a and low VEGF
was inferior to when Wnt5a was analyzed in combination with AR
or Ki-67 indicating that VEGF in not as strong as AR or Ki-67 to
predict outcome in combination with Wnt5a in the present context
(Fig. 2D). Cox regressional analysis was used for multivariate
analyses and revealed that Wnt5a expression, Gleason score and
pathological T stage were independent factors influencing relapse
free survival in PCa (Table 4).
Wnt5a protein expression and its effects on invasion and
proliferation of PCa cell lines
Our data show that patients with high Wnt5a protein expression
have more favorable outcome compared to patients with low
Table 2. Scoring data from Wnt5a, AR, VEGF and Ki-67 immunostained cores from benign and cancer tissues in duplicates
mounted in a TMA.
Wnt5a AR VEGF Ki-67
Score Benign Cancer Benign Cancer Benign Cancer Benign Cancer
0 60 (15) 14 (4) 6 (1.5) 2 (0.5) 14 (3) 16 (5) 55 (14.2) 21 (5.3)
1 205 (50) 53 (14) 186 (45.6) 126 (30.1) 184 (46) 80 (23) 323 (83.2) 341 (85.5)
2 123 (30) 162 (44) 165 (40.4) 179 (42.7) 175 (44) 180 (52) 9 (2.3) 33 (8.3)
3 19 (5) 141 (38) 51 (12.5) 112 (26.7) 29 (7) 72 (21) 1 (0.2) 4 (1)
Total 407 (100) 370 (100) 408 (100) 419 (100) 402 (100) 348 (100) 388 (100) 431 (100)
Missing 57 94 56 45 62 116 76 65
Total 464 464 464 464 464 464 464 464
p-value ,0.0001 ,0.0001 ,0.0001 ,0.0001
Scoring is based on arbitrary units with 0 representing no staining, 1 as weak staining, 2 as moderate staining and 3 as strong staining. For Ki-67 the percentage of
nuclear positivity was scored as 0 (0–1% positive nuclei), 1 (1–3% positive nuclei), 2 (4–10% positive nuclei) and 3 (11–20% positive nuclei). The p values at the bottom
row of the table indicate statistically significant differences between benign and cancer samples from same patient when Wilcoxon rank sum tests were performed. The
values in the brackets represent number of patients (%) based on the highest score from each individual duplicate. Patients who underwent radiation therapy and/or
hormonal therapy before radical prostatectomy were excluded from the IHC analysis.
doi:10.1371/journal.pone.0026539.t002
Table 3. Spearman’s correlation coefficients (r) when Wnt5a
protein expression was analyzed for possible correlation with
other tissue biomarkers in the cancer cores from 464 PCa
patients.
Ki-67 AR VEGF
Wnt5a r 0.212
** 0.142
** 0.395
**
p-value ,0.0001 0.007 ,0.0001
**Correlation is significant at the 0.01 level (2-tailed).
doi:10.1371/journal.pone.0026539.t003
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Wnt5a protein expression in one SV40 immortalized normal
human prostate epithelial cell line (PNT2) and four different PCa
cell lines were examined. PNT2 cells had a low expression of
endogenous Wnt5a protein whereas there was considerable Wnt5a
expression in the PCa cell lines LNCaP and 22Rv1 (Fig. 3A).
These data are in good agreement with our findings of Wnt5a
protein expression in the presently analyzed cohort of PCa and a
recent study also performed on normal prostate epithelial and PCa
cell lines [26]. However, analyses of the two more aggressive PCa
cell lines (PC3 and DU145) revealed very low expression of Wnt5a
protein, comparable to that of the normal PNT2 prostate
epithelial cell line (Fig. 3A). Interestingly enough, the Wnt5a
protein levels matched with the AR protein expressions in these
cell lines (Fig. 3A).
We used the four cancer cell lines (LNCaP, 22Rv1, PC3 and
DU145) for our subsequent invasion experiments. Addition of
recombinant Wnt5a (rWnt5a) decreased the invasive behavior of
both 22Rv1 and DU145 cancer cells (Fig. 3B). Neither the
LNCaP nor the PC3 cells did respond to rWnt5a with a change in
their invasive behavior. The result with the PC3 cells is in
accordance to a recently published report by Wang et al [26], in
which PC3 cells did not respond to addition of rWnt5a in a
migration wound scratch assay. LNCaP cells are known to have a
very low invasion activity, and this might explain why these cells
did not respond when rWnt5a was added. However, when Wnt5a
expression in LNCaP cells was knocked down using si-RNAs
(Fig. 3E), there was a significant increase in the invasive behavior
of LNCaP cells (Fig. 3F). In addition, Wnt5a knockdown by si-
RNA in 22Rv1 cancer cells also resulted in increased invasion of
these cells (Fig. 3E–F and Figure S4).
To find out whether the decrease in invasion of 22Rv1 and
DU145 cell lines with the addition of rWnt5a was due to decrease
in proliferation of these cell lines, we investigated the proliferation
rate in PCa cell lines. Addition of rWnt5a did not have any
significant effect on proliferation in these cell lines during the
24 hours used for the invasion assay (Fig. 3C).
Since rWnt5a decreased the invasion of 22Rv1 and DU145
cells, invasion assay was also performed in these cell lines using
Foxy5 which is a hexapeptide derived from the amino acid
sequence of Wnt5a protein and previously shown to inhibit
motility of breast cancer cells like rWnt5a [30]. Foxy5 indeed
repressed invasive capabilities of these two PCa cell lines (Fig. 3D),
and this decrease in invasion was not caused by decreased
proliferation as Foxy5 did not affect the proliferation status in
these cell lines (BrdU assay, data not shown).
Discussion
To our knowledge, this far only one study with a limited
number of patients has demonstrated a role of Wnt5a protein to
predict clinical outcome in PCa [25]. This urged us to perform a
study on Wnt5a protein expression in a larger cohort of well-
defined PCa patients with localized and predominantly low-grade
disease and relate the results with the expression of other known
tissue biomarkers and most importantly with BCR. The present
study involved a consecutive series of 503 PCa patients that had
undergone radical prostatectomy during 1988–2003 at Ska ˚ne
University Hospital, Malmo ¨, Sweden with a mean follow-up time
of 41.6 month (range 1.51–205.90). This patient cohort is large,
population based, and the patients are well characterized
(Table 1). In the TMA slides benign and malignant tissues from
the same patient are present in duplicates. Based on Gleason
grades patient material was further characterized into low-grade
cancers (Gleason score up to 3+4) and high-grade cancers
(Gleason 4+3 or higher). Almost 89% of the patients were
classified as low-grade cancers, which is to be expected in a group
of patients with localized PCa suitable for radical prostatectomy.
Table 4. Multivariate analysis of factors influencing biochemical relapse-free survival.
Factors Groups n (%) Hazard ratio (95% CI) x
2 p - value
Wnt5a Staining High 321 (80.7) 1 (Reference) 10.863 0.001
Low 77 (19.3) 2.204 (1.361–3.570)
Wnt5a & Ki67 staining Wnt5a high Ki67 low 255 (73.1) 1 (Reference) 36.638
Wnt5a low Ki67 low 59 (16.9) 2.335 (1.344–4.054) 0.003
Wnt5a low Ki67 high 3 (0.6) 14.501 (4.412–47.658) ,0.0001
Wnt5a high Ki67 high 32 (9.2) 2.215 (1.128–4.351) 0.021
Wnt5a & AR staining Wnt5a high AR low 81 (22.2) 1 (Reference) 19.769
Wnt5a low AR low 28 (7.7) 3.044 (1.067–8.685) 0.037
Wnt5a low AR high 36 (9.9) 6.060 (2.489–14.756) ,0.0001
Wnt5a high AR high 220 (60.3) 2.503 (1.129–5.546) 0.024
Wnt5a & VEGF staining Wnt5a high VEGF low 63 (18.6) 1 (Reference) 13.955
Wnt5a low VEGF low 29 (8.6) 2.843 (1.121–7.211) 0.028
Wnt5a low VEGF high 28 (8.3) 3.501 (1.407–8.712) 0.007
Wnt5a high VEGF high 219 (64.6) 1.323 (0.617–2.836) 0.472
Path. Gleason Score #3+4 398 (90.5) 1 (Reference) 9.302 0.002
$4+3 42 (9.5) 2.247 (1.317–3.835)
Path. T Stage T2 226 (50.4) 1 (Reference) 22.05 ,0.0001
T3 222 (49.6) 2.655 (1.738–4.056)
n=Frequency; CI=Confidence Interval; x
2=Chi-Square; Path.=Pathological.
doi:10.1371/journal.pone.0026539.t004
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a statistically significant difference in clinical outcome between
patients with low-grade and high-grade cancer using Kaplan-
Meier analyses of BCR-free survival (Figure S2A). Further
control of the clinical material also revealed that the same was true
when proliferation was studied by Ki-67 expression, a validated
tissue biomarker in PCa [31]. Patients with high Ki-67 expression
had reduced relapse free survival time when compared with
patients with a low number of Ki-67 expressing tumor cells
(Figure S2B).
In the present TMA study we used a well characterized in-house
antibody specific for Wnt5a as previously described in breast
cancer studies [20]. Here, we also performed competition with
rWnt5a to confirm the specificity of the antibody on prostatic
tissue sections (Figure S3). The staining intensity decreased from
antibody alone to when antibody and rWnt5a were used and
already at a molar ratio of 1:10 we found a clear reduction of the
immunostaining. In addition, we carried out immunocytochem-
istry (Supplementary Materials and Methods S1) of Wnt5a
in prostate cancer cell lines (LNCaP, 22Rv1 and DU145) after
pretreatment with either scrambled or Wnt5a si-RNA (Figure
S4A,B,C,D,E). First, we observed cytosolic staining of Wnt5a
similar to that observed in the prostate cancer tissue and secondly,
the intensity of Wnt5a immunostaining decreased significantly in
the Wnt5a si-RNA treated cells compared with those treated with
scrambled si-RNA. Treatment with Wnt5a siRNA decreased the
degree of Wnt5a immunostaining to a level similar to that seen in
the Western blots (Fig. 3E). Analysis of our TMA clearly show
that Wnt5a protein expression was increased in localized PCa
when compared to benign tissue from the same patients, an effect
that exhibited a strong statistical significance (p,0.0001; Fig. 1 A,
B & G, Table 2). These results are in good agreement with the
recent findings obtained from a smaller cohort [25]. The clinical
conclusion that Wnt5a protein expression is increased in localized
PCa tissue compared with normal/benign tissue is also supported
by our analysis of different human prostate cell lines. We clearly
observed that the PNT2 cell line, an SV40 immortalized cell line
derived from normal human prostate epithelium express very low
levels of endogenous Wnt5a protein, whereas the expression of
Wnt5a protein was high in the PCa cell lines LNCaP and 22Rv1.
The more aggressive cell lines, PC3 and DU145, had a very low
Wnt5a protein expression. This is in line with the less favorable
outcome observed in Wnt5 low tumors. However, in the TMA
material, Wnt5a was not downregulated in the high-grade
(Gleason score .4+3) PCa cases. If these seemingly contradicting
results indicate a grade-unrelated function of Wnt5a or only reflect
Figure 2. Analysis of how Wnt5a protein expression alone or in combination with other biomarkers affects the clinical outcome of
PCa patients. All cancer cases were separated into 2 groups based on the staining intensities of Wnt5a, Ki-67, AR and VEGF. The low groups
included tumors with scores 0 or 1 and the high groups included tumors with scores 2 or 3. A) The panel shows survival curves plotted between high
or low Wnt5a protein expression and BCR free time. B) The panel shows survival curves plotted between high or low Wnt5a and high and low Ki-67
protein expressions. Consequently, the tumors were divided into the following 4 groups; Wnt5a low & Ki-67 low, Wnt5a low & Ki-67 high, Wnt5a high
& Ki-67 low and Wnt5a high & Ki-67 high. C The panel shows survival curves plotted between high or low Wnt5a and high and low AR protein
expressions. Consequently, the tumors were divided into the following 4 groups; Wnt5a low & AR low, Wnt5a low & AR high, Wnt5a high & AR low
and Wnt5a high & AR high. D) The panel shows survival curves plotted between high or low Wnt5a and high and low VEGF protein expressions.
Consequently, the tumors were divided into the following 4 groups; Wnt5a low & VEGF low, Wnt5a low & VEGF high, Wnt5a high & VEGF low and
Wnt5a high & VEGF high. In all panels high expression of a protein is indicated by q whereas Q indicates low expression. Each step in the curves
represent relapse in PCa. The given p-values at the bottom right hand side of the panels indicate significant differences in outcome between the
most favorable group and the least favorable group (see Table 4 for more detailed information).
doi:10.1371/journal.pone.0026539.g002
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lines were derived is hard to say. As an alternative explanation, the
number of high-grade PCa in the present cohort (n=41) might be
too small to detect a grade-related Wnt5a down-regulation.
We also found increased expression of AR, Ki-67 and VEGF
proteins in localized PCa tissue compared to benign tissue (Fig. 1
C–F, H–I, Table 2). To obtain a first insight into possible
mechanisms for how Wnt5a functions in PCa, we performed
statistical analyses of potential correlations between Wnt5a protein
expression and that of AR, Ki-67 and VEGF, all three well-known
to be upregulated in progressive PCa. Wnt5a significantly
correlated with VEGF, a marker for angiogenesis, indicating that
Wnt5a might be related to tumor growth (Table 3). In this regard
our data is somewhat different from those reported from analyses
of non-small cell lung cancer where Wnt5a did not correlate with
VEGF expression in the cancer tissue but with VEGF in the
surrounding stromal tissue [32]. Furthermore, Wnt5a expression
in PCa tissue in our study weakly but significantly associated with
Figure 3. Analysis of Wnt5a protein expression in different prostate cell lines and its effect on PCa cell invasiveness and
proliferation. A) This panel shows the endogenous Wnt5a and AR expression in four indicated PCa cell lines (LNCaP, 22Rv1, DU145 and PC3 cells)
and in one immortalized human prostate epithelial cell line (PNT2 cells). Wnt5a protein band was identified by running rWnt5a in parallel on the same
gel. The blots were reprobed for b-actin as loading control. The presented blots are representative of 4 separate experiments. B) The panel outlines
the relative invasion of LNCaP, 22Rv1, DU145 and PC3 cell lines after 24 h in the absence or presence of rWnt5a (0.4 mg/ml) in the assay described in
the Materials and Methods section. The results are given as means 6 SEM from 5 separate experiments. The differences in invasion between cells
treated with vehicle alone or with rWnt5a were evaluated for statistical significance (p=0.0001 for 22Rv1 and p,0.0001 for DU145). C) The panel
outlines the proliferation of LNCaP, 22Rv1, DU145 and PC3 cell lines after 24 h in the absence or presence of rWnt5a (0.4 mg/ml). The results are given
as means 6 SEM from 5 separate experiments. There were no significant differences in proliferation between control and rWnt5a treated cells. D) The
panel represents the relative invasion of 22Rv1 and DU145 cells after 24 h in the absence or presence of Foxy5 (100 mM) using the same assay as in
panel B. The differences in invasion between cells treated with vehicle alone or with Foxy5 were evaluated for statistical significance (p=0.01 for
22Rv1 and p=0.0003 for DU145). E) The panel depicts the effects of siRNA knockdown of Wnt5a in LNCaP and 22Rv1. The blots were reprobed for a-
tubulin as loading control. The presented blots are representative of 4 separate experiments. F) The panel outlines the relative invasion of LNCaP and
22Rv1 cells after treatment with Wnt5a si-RNA (Wnt5a knockdown) or scrambled siRNA (control), in the same assay previously used in panel B. The
results are given as means 6 SEM from 5 separate experiments. The difference in invasion between scrambled and si-Wnt5a knocked down cells were
statistically significant for both cell lines (p,0.0001).
doi:10.1371/journal.pone.0026539.g003
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blot indicated that Wnt5a levels and AR expression in one
immortalized prostate epithelial cell line and 4 different PCa cell
lines matched with each other, indicating a possible correlation
between Wnt5a and AR in PCa (Fig. 3A). Despite these data, it
has been recently shown that Wnt5a inhibits AR transcriptional
activity in 22Rv1 cells when these cells were transfected with a
Wnt5a plasmid [33]. Finally, Wnt5a protein expression was
weakly but significantly associated with Ki-67 expression
(Table 3). This result is in accordance with the report on Non-
small-cell lung cancer, where intratumoral Wnt5a expression
significantly correlated with Ki-67 proliferation index [32], but in
contrast to the study on hepatocellular carcinoma where Wnt5a
has a tumor suppressing effect and loss of Wnt5a has a strong
correlation with high Ki-67 proliferation index [34]. Taken
together these data indicate that the role of Wnt5a signaling in
the regulation of tumor cell proliferation is uncertain.
In the present investigation we did not find a correlation
between Wnt5a protein expression and the Gleason score,
although the latter may be the best available prognostic indicator
of outcome in PCa [35]. However, Gleason scoring has its
limitations due to interobserver variability among pathologists and
hence there is a need for complementary markers. To determine
whether or not Wnt5a protein expression can be used to predict
outcome (relapse-free survival) after surgery in patients with
localized PCa in this population-based cohort, Kaplan-Meier
curves were plotted between Wnt5a protein expression and BCR
free time (Fig. 2A). Interestingly, patients with high Wnt5a protein
expression had a statistically significant more favorable outcome
compared to patients with low Wnt5a protein expression
indicating that the Wnt5a protein has a tumor suppressive
function in the context of localized PCa. In majority of cases,
Wnt5a signaling has opposite effects than Wnt/b-catenin
signaling, for example in malignant melanoma [36]. Although a
different and more advanced PCa patient material was used by
Chen and co-workers, their finding that Wnt1 and b-catenin
expression can serve as markers for PCa progression [12] is
compatible with our data that Wnt5a predicts a more favorable
outcome in PCa patients.
Combining Wnt5a protein expression with other well-known
PCa markers could further improve the predictive power of Wnt5a
as previously mentioned. The hypothesis that Wnt5a has a tumor
suppressive function was further supported by our invasion data in
three of four PCa cell lines investigated. Addition of rWnt5a led to
decrease in invasion in 22Rv1 and DU145 cells. It was not
surprising that LNCaP cells, known to have a very low invasive
behavior, did not exhibit a detectable further reduction in its
invasive behavior in response to rWnt5a. Upon further investiga-
tion we found that the rWnt5a effect in 22Rv1 and DU145 cells is
specific on the invasion of these cells and not because of its toxicity
to these cells or has any adverse effect on proliferation of these cell
lines. In both cell lines rWnt5a triggered a prompt and transient
rise in the cytosolic free calcium level (Supplementary
Materials and Methods S1; Figure S5A,B), indicative of a
ligand-receptor interaction. If there would have been a toxic effect
of rWnt5a one would have anticipated a slow increase that then
remained elevated, but this was not the case. Furthermore, if the
effect of rWnt5a would be toxic one would also have anticipated a
reduction of BrdU positive cells, which we did not see. Addition of
rWnt5a did not have a significant effect on proliferation of these
cells. However, Wnt5a knockdown experiments were performed
on LNCaP cells, as well as on 22Rv1 cells, Wnt5a siRNAs
increased the invasive activity of LNCaP and 22Rv1 cells;
indicating that for PCa cells to invade, Wnt5a must be actively
silenced. Like rWnt5a, Foxy5 (a Wnt5a-derived hexapeptide) also
affected invasion in 22Rv1 and DU145 cells without having an
effect on proliferation of these cell lines. These results are in
accordance with an earlier report published from our group on
breast cancer metastasis where neither rWNt5a nor Foxy5 affected
proliferation or apoptosis but inhibited migration and invasion in
4T1 breast cancer cells [37].
It has recently been suggested that Wnt5a promotes aggressive-
ness of PCa and patients with low/negative Wnt5a expression
have better relapse free survival after radical prostatectomy [25].
These results are quite in contrast to our findings. Their
contrasting results can be attributed to less patient samples and
the fact that in their material 24.5% (24 out of 98 patients) of the
tumors had a Gleason score of 8 or higher, whereas in our study
only 11% of the tumors had such a high Gleason score.
Furthermore, different Wnt5a antibodies were used in the two
studies. Our Wnt5a antibody has been evaluated by peptide
blocking experiments during IHC [20], loss of Wnt5a following
siRNA knockdown and Wnt5a overexpression. However, it cannot
be excluded that Wnt5a exerts different effects on tumor
progression in different stages of the disease. Our different results
from the in vitro invasion assay can possibly be explained by the fact
that we have used a defined concentration of rWnt5a and the
other group used cells transfected to over-express Wnt5a without
any control of the actual stimulating concentration of Wnt5a.
There are studies within the scientific community on the
possible role of Wnt5a in suppressing or promoting tumor
progression. It must be pointed out that an upregulation of
Wnt5a mRNA in a specific cancer type does not alone indicate a
tumor promoting function, since this might very well go hand in
hand with a reduced Wnt5a protein level. Even if this is taken into
account it appears as if Wnt5a has different functions in different
types of tumors [16]. In conclusion, our study indicates that
although Wnt5a protein expression is elevated in PCa, its
expression in PCa cells is associated with a more favorable
outcome for patients with localized disease. One important
mechanism for such an effect of Wnt5a in PCa progression is
the present demonstration that Wnt5a can impair the invasive
behavior of PCa cells in vitro. Taken together, our results suggest a
novel therapeutic approach for patients with localized PCa by
targeting Wnt5a to impair progression of PCa in these patients.
Materials and Methods
Ethics statement
This study was performed after approval from Regional Ethical
Review Board in Lund. Archival tissue specimens from 503
patients operated on between 1988 and 2003 were used in the
present study. Since some of the samples were old, and were from
different parts of the region, it was not possible to obtain written
consent from each patient. Detailed information describing the
study and TMA construction was published in 2004 in a daily
newspaper and patients had a free choice of written or verbal
informed consent as they were offered to contact us by mail or by
phone if they had any objections. None of the 503 patients
declined. This procedure was done strictly following guidelines
from Regional Ethical Review Board in Lund who approved the
procedure.
Patients and tissue microarray (TMA) construct
A TMA was constructed from a population-based cohort of 503
PCa patients who underwent radical prostatectomy between 1988
and 2003 at the Department of Urology, Ska ˚ne University
Hospital, Malmo ¨, Sweden as previously described [38]. From each
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a total of 17 paraffin blocks. Consecutive sections were used for
IHC. A senior National Board certified pathologist (LH) examined
hematoxylin & eosin stained tissues for Gleason grade and for the
presence of prostatic intraepithelial neoplasia. The clinical and
pathological characteristics of the PCa patients were obtained
from reading the patient charts in detail (DU and AB) and are
shown in Table 1. The mean follow-up time was 41.6 months
(range 1.51–205.90). BCR was defined as a blood PSA level of at
least 0.2 ng/ml with a subsequent confirmatory value.
Source of antibodies
The following antibodies were used for immunostainings:
Wnt5a (rabbit polyclonal): antibody was developed in our
laboratory against a Wnt5a sequence with 100% homology
between human and mouse [20]; androgen receptor (AR) (code
AR 441, mouse monoclonal, Thermo Fisher Scientific Inc.,
Freemont, CA), Ki-67 (mouse monoclonal, MIB-1 code M7240,
Dako Denmark A/S, Glostrup, Denmark); VEGF A-20 (rabbit
polyclonal, code sc-152, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA); b-actin (mouse monoclonal, code C4, MP Biomedicals,
Solon, OH), a Tubulin (mouse monoclonal, sc-32293, Santa Cruz
Biotechnology).
Immunohistochemistry (IHC)
Consecutive sections of 4 mm thicknesses were mounted on
Superfrost Plus (Menzel Gla ¨ser, Braunschweig, Germany) glass
slides and de-paraffinized with xylene and rehydrated in
decreasing concentrations of ethanol solutions. For antigen
retrieval TMA slides were heated in PT Link (Dako) from 65uC
to 98uC for 40 min and then processed for immunohistochemical
staining for Wnt5a (final dilution 1:100), AR (1:100), Ki67 (1:100)
and VEGF (1:100) using EnVision
TM Flex, High pH reagent (code
K8010, Dako) in Autostainer Plus according to the manufacturer’s
protocol (Dako). Immunostaining of Wnt5a, Ki-67, AR and
VEGF were scored independently by pathologists LH, AE and
RE. Overall, scoring pattern matched in nearly 80% of cases in
staining intensities as well as percentage of positive cells.
Remaining 20% cases where there was a disagreement over
scoring were re-examined together and were scored after coming
to a conclusion. In general, the cores were scored 0 (no staining), 1
(weak staining), 2 (moderate staining) or 3 (strong staining) based
on the staining intensities and/or percentage of positive cells.
Wnt5a and VEGF slides were scored based on the cytoplasmic
staining whereas nuclear staining was evaluated for AR staining.
Ki-67 slides were scored as 0 (0–1%), 1 (1–3%), 2 (4–10%) and 3
(11–20%) based on nuclear fraction positivity. While performing
statistics protein expression scores were separated into two groups
based on their staining intensities; scores 0 & 1 are grouped as
weak/low and strong/high group contains scores of 2 & 3.
For IHC studies and correlation analyses on Wnt5a, Ki-67, AR
and VEGF, patients with no Gleason score information available
(29), and patients who received hormonal and/or radiation
therapy (39) were excluded, leaving 464 patients for analyses.
During TMA construction some cores were either lost, or were not
properly placed on slides, or were damaged and were not available
to score; hence immunostaining data of proteins contains missing
values (Table 2).
We also performed competition with recombinant Wnt5a to
confirm the specificity of the Wnt5a antibody. Prostate cancer
cores were immunostained with either the Wnt5a antibody alone
(Figure S3A) or with the Wnt5a antibody supplemented with
recombinant Wnt5a (molar ratio 1:1 (Figure S3B) and 1:10
(Figure S3C)). The staining intensity decreased from antibody
alone to when antibody and rWnt5a were used and already at a
molar ratio of 1:10 we found a clear reduction of the
immunoreaction.
Cell lines
Four human PCa cell lines LNCaP, 22Rv1, PC-3, and DU145
were purchased from American Type Culture Collection [ATCC]
(Manassas, VA). The immortalized PNT2 normal human prostate
epithelial cells (cat No. 95012613) were obtained from European
Collection of Cell Cultures (ECACC), (Sigma-Aldrich, St. Louis,
MO). LNCaP, 22Rv1, DU145 and PNT2 cells lines were cultured
in RPMI-1640 medium, supplemented with 10% fetal bovine
serum (FBS) and 1% pest (penicillin and streptomycin). PC-3 cells
were grown in Hyclone Ham’s F12 medium supplemented with
10% FBS and 1% pest. All in vitro experiments were performed
when cells were ,70% confluent. For invasion assay experiments
cells were grown in serum free medium (SFM) for 24 hours.
RPMI-1640 medium (R0883), FBS (F6178), penicillin-streptomy-
cin (P0781) were purchased from Sigma-Aldrich, whereas Ham’s
F12 medium (SH30026.01) was obtained from Thermo-Scientific
(Waltham, MA). All cell lines were regularly tested for the absence
of mycoplasma infection.
Western blot Analysis
Protein expression was examined by western blot analysis. In
brief, cells were washed with PBS, trypsinized (in trypsin for
3 min), centrifuged at 1000 rpm for 4 minutes. Cells were lysed on
ice in RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1%
Triton x-100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 1 mM EDTA, 0.1 mg/mL Phenylmethylsulphonyl fluo-
ride with the addition of Complete Mini protease inhibitor cocktail
(Roche, Mannheim, Germany) for 30 min, centrifuged at
15,000 rpm for 25 min at +4uC, and protein lysates were collected
as supernatants. After measuring protein concentration by
Bradford assay, 100 mg of each protein sample was loaded on
10% SDS – polyacrylamide gels. Proteins were separated using gel
electrophoresis and transferred to Hybond ECL nitrocellulose
membranes (Amersham Pharmacia Biotech, Buckinghamshire,
UK). For blocking of non-specific binding, nitrocellulose mem-
brane was blocked in 5% dry milk for 45 min at room
temperature, washed twice in buffer (0.05% Tween in PBS) for
10 min, and then incubated overnight separately with rabbit
polyclonal Wnt5a antibody (1:750 in 2.5% dry milk) or mouse
monoclonal AR (1:500 in 2.5% dry milk) at +4uC. After
incubation (for 60 min at room temperature) with horseradish
peroxidase – conjugated anti-rabbit secondary antibody (Amer-
sham Life Science, Alesbury, UK) (1:10000 in 5% dry milk) for
Wnt5a and horseradish peroxidase – conjugated goat anti-mouse
secondary antibody (Dako) (1:10000 in 5% dry milk) for AR and
washing away the unbound antibodies, membrane-bound anti-
body was detected by using Western blotting Luminol Reagent
(Santa Cruz). Membranes were then stripped using stripping
solution (Restore PLUS Western Blot Stripping Buffer, Thermo
Scientific) and reprobed for b-actin (1:3,000 in 2.5% dry milk) or a
Tubulin(1:1000 in 2.5% dry milk).
Transfection with Wnt5a siRNA
Two different SilencerH Select Pre-designed (Inventoried)
Wnt5a siRNAs (S1 and S2) and SilencerH Select negative control
siRNA were purchased from Applied Biosystems (Ambion, CA). A
cocktail of two different siRNAs (120 nM) in nuclease-free water
was transfected into 1610
5 cells in a total volume 250 mL of serum
free medium using 10 mL of Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Media was changed after 5 hours of transfection.
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cells were used 24 hours later for analysis of their Wnt5a protein
expression and invasive capacities.
Invasion Assay
Cell invasion capacities were measured in a standard commer-
cial invasion assay. In this study we used BD BioCoat
TM
Matrigel
TM Invasion Chambers (BD Biosciences, Bedford, MA)
in accordance with the manufacturer’s protocol. Briefly, cells were
grown in SFM for 24 h, harvested using versene (Invitrogen,
Carlsbad, CA), washed in PBS and resuspended at a concentration
of 50,000 cells/ml in SFM. To the lower well 0.7 ml serum
containing medium (10% FBS) was added. To the invasion
chamber 0.5 ml (25,000 cells) of the cell suspension, containing
either 0.4 mg/ml recombinant Wnt5a (rWnt5a, R&D Systems,
Minneapolis, MN), or 100 mM Foxy5 (formyl-Met-Asp-Gly-Cys-
Glu-Leu peptide, Pepscan Systems, Lelystad, Netherlands) or PBS
(with 0.2% BSA) was added, and were incubated for 24 h at 37uC.
After 24 h cells that invaded through the Matrigel were fixed in
4% paraformaldehyde and stained with 0.2% crystal violet in 20%
methanol (Sigma-Aldrich, Saint Louis, MO, USA). Remains of the
Matrigel were removed with a cotton stick moistened in PBS.
Membranes from invasion chambers were separated and mounted
on glass slide using VectaShieldH mounting medium with DAPI
(Vector Laboratories, Burlingame, CA). Invaded cells were
counted either in an inverted microscope or in Olympus BX51
Fluorescence Microscope (Olympus optical Co. Ltd, Japan).
Proliferation Assay
Cell proliferation assay was performed in LNCaP, 22Rv1,
DU145 and PC-3 cells using Cell Proliferation BrdU kit version
13.0 (11647229001, Roche diagnostics, Mannheim, Germany)
according to manufacturer’s instructions. Briefly, 25000 cells with
BrdU labeling solution were seeded in 96-well plate and incubated
with either vehicle (0.01%BSA in PBS) or rWnt5a (0.4 mg/mL) for
24 h in 37uC incubator. After 24 h, cells were fixed for 30 min,
incubated with anti-BrdU-POD for 90 min at room temperature
and washed. Absorbance of the samples was measured in an
ELISA reader at 370 nm (reference wavelength 492 nm) at
multiple time points (e.g., 4, 8 and 12 min) after substrate solution
was added. The results presented here are absorbance values after
4 minutes.
Statistical analysis
All statistical analyses were performed using SPSS version 17.0
(SPSS, Chicago, IL) and Microsoft Excel 2010. Since patients’
samples were present in duplicates, the best score of the two cores
(if available) was used for statistical analyses. Patients receiving
preoperative hormonal treatment or radiation therapy (n=39),
patients with no information available on Gleason score (29) and
the patients where PSA levels were not completely 0 after radical
prostatectomy and hence no BCR (n=75) were excluded, leaving
a total of 397 patients for survival and multivariate statistical
analyses. For statistical analyses patient material was divided into
two groups based on Gleason scoring; patients with Gleason score
5 to 7 (with 3+4 cases only) were grouped as ‘‘low-grade cancers’’,
and patients with Gleason score 7 (4+3 cases only) to 10 were put
together as ‘‘high-grade cancer’’ group. Wilcoxon Signed Ranks
test was used to examine any significant difference in Wnt5a
protein expression between cancer and benign tissues. Spearman’s
rank-order correlation was performed to know significant
correlations between Wnt5a, AR, Ki-67 and VEGF staining.
Kaplan-Meier method was used to determine BCR-free survival
(outcome) and Log Rank (Mantel-Cox) test was used to compare
BCR free survival among different Wnt5a expression groups. For
survival analysis staining intensities of different proteins were
grouped into two; no/weak staining in group ‘‘1’’ (low) and
moderate/strong staining in group ‘‘2’’ (high). In some analyses,
expression pattern of two different proteins were grouped together,
for example, while performing survival curves and Cox regres-
sional analyses Wnt5a and AR staining intensities were grouped
together, making four different groups. Patients with low Wnt5a
and low AR staining constituted group 1, group 2 had patients
with low Wnt5a and high AR staining, patients with high Wnt5a
and low AR were kept in group 3, whereas group 4 consisted of
patients with high Wnt5a and high AR staining intensities. The
same criterion was applied while combining Wnt5a staining
intensities with Ki-67/VEGF scorings.
Supporting Information
Materials and Methods S1
(DOC)
Figure S1 Representatives of Ki-67 nuclear fraction immuno-
stainings. A) The panel represents cancer core with no Ki-67
nuclear staining. B) The panel represents cancer core with 1–3%
Ki-67 nuclear staining, C) The panel shows cancer core with 4–
10% of nuclei stained positive for Ki-67 D) The panel shows
cancer core with more than 10% of nuclei stained positive for Ki-
67. All inserts in the panels depict magnification (406) images of
the area indicated by the arrow in the larger image seen at 156
magnification. The bar in each panel outlines 100 mm.
(TIF)
Figure S2 Validation of the patient material used in this study.
A) The patient tumor material was divided into 2 groups based on
their Gleason score (GS). As indicated in the panel one group had
a Gleason score of #3+4 and the other a Gleason score of $4+3.
Kaplan-Meier curves were then generated for each of the 2 groups
with the indicated Gleason scores and their respective BCR free
time. B) The panel shows Kaplan-Meier curves plotted between
low or high Ki-67 expression and their respective BCR free time.
C) The panel shows Kaplan-Meier curves plotted between low or
high AR expression and their respective BCR free time. D) The
panel shows Kaplan-Meier curves plotted between low or high
VEGF expression and their respective BCR free time.
(TIF)
Figure S3 Validation of Wnt5a antibody specificity by blocking
with rWnt5a. A shows a prostate cancer core section immuno-
stained with anti-Wnt5a IgGs alone. B&C ) Adjacent tissue
sections immunostained using the same Wnt5a antibody after pre-
incubated with rWnt5a at a molar ratio of 1:1 or 1:10, respectively.
Each bar outlines 100 mm.
(TIF)
Figure S4 Immunocytochemistry of prostate cancer cell lines
after Wnt5a knockdown using si-RNA, immunostained with
Wnt5a antibody. A) Wnt5a staining in LNCaP cells transfected
with scramble RNA. B) Decreased intensity of Wnt5a staining in
LNCaP cells transfected with si-Wnt5a. C) Wnt5a staining of
22Rv1 cells transfected with scramble RNA. D) Decreased Wnt5a
staining in 22Rv1 cells transfected with si-Wnt5a. E) Weak Wnt5a
immunostaining in DU145 cells.
(TIF)
Figure S5 Measurement of intracellular Ca
2+ signaling in
DU145 (A) and 22Rv1 (B) cell lines. Addition of rWnt5a
(10 mg/ml) indicated by arrows.
(TIF)
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